Company intelligence / Profile preview

Soteri Skin

San Francisco, California, United Statessoteriskin.com ↗

Ownership: Private
Development stage: Commercial

Overview

Soteri Skin’s patented pH/LOCK™ technology has demonstrated clinically proven results for eczema relief. Clinical trials showed that over half of participants experienced complete symptom relief and all saw improvement in overall skin health. The products are steroid-free, non-prescription topical treatments designed to restore the acid mantle and correct the root cause of eczema by stabilizing skin pH for up to twelve hours.

Therapeutic areas: Dermatology
Modalities: Non-pharmacological therapyDeviceBiologicSmall molecule
Industry: Consumable Medical Devices

Drug pipeline

5 assets

No More Rough Patches

Commercial

Indications: Eczema

4 more assets in the full pipeline.

Request access →

Partnerships

Y Combinator accelerator participant/investorLaunch Lab X investor

Beyond the preview

Go deeper on Soteri Skin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Soteri Skin.

Explore the full profile